Bench to bedside and back again with BRAF and NRAS mutant cancers

Can we improve responses to Zelboraf in advanced melanoma? The answer is a startling yes.

May 6, 2014

6 important things I learned from AACR 2014 on immuno-oncology

Insights on checkpoint inhibitors, co-stimulants, CAR T cell therapy and bispecific antibody TCRs

May 2, 2014

New directions in immuno-oncology in biomarkers and combinations

Update on emerging potential immuno-oncology biomarkers and combinations from AACR

April 30, 2014

AACR 2014: Review of novel targeted approaches in lung and prostate cancers

Overcoming acquired resistance to therapy is a major focus in lung and prostate cancers. Check out the new developments from AACR.

April 22, 2014

Promising new targeted cancer agents emerge at AACR 2014

Exciting new data was seen at AACR this year, including a novel ADC with a new target in melanoma, a metabolic target and understanding adaptive resistance to PI3K in breast cancer.

April 17, 2014

Next generation FGFR inhibitors are early but promising in selected cancers

After disappointing results from FGFR inhibitors brivanib and dovitinib, can the next generation compounds overcome scepticism and offer better efficacy?

April 16, 2014

Insights from AACR on immunotherapy and checkpoint inhibitors

Immunotherapy is coming of age despite the chequered history in the past with vaccines. In part 1 we explore the state of play in lung cancer.

April 15, 2014

Super Enhancers – what are they and why do they matter in cancer research?

Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.

April 14, 2014

Pfizer’s palbociclib data in ER+ breast cancer – hit or miss?

Pfizer's palbociclib showed promising survival data at the AACR annual meeting this weekend, but is it enough to garner approval on the basis of the phase II data?

April 8, 2014

The real story behind Juno’s CAR T cell therapy suspensions

This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.

April 6, 2014

Innate immunotherapy – is it ready for prime time in cancer research?

A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.

April 2, 2014

Novel targets and approaches in triple negative breast cancer

What are the new targets and drug combinations that are emerging in triple negative breast cancer (TNBC)? find out more about the promising developments in this field.

April 1, 2014

AACR 2014 Preview: Novel targets and approaches

Review of some interesting cancer pipeline drugs at AACR 2014 including TKIs and ADC therapies.

March 27, 2014

What can we learn from exceptional responders in cancer trials?

Following on from yesterday’s post on the potential for small basket trials in ER+ breast cancer with…

March 26, 2014

Do ESR1 mutations drive endocrine resistance during the progression of ER+ breast cancer?

Today brings the launch of our series on the AACR annual meeting Previews.  A variety of different…

March 25, 2014